Review



recombinant human cd40l  (R&D Systems)


Bioz Verified Symbol R&D Systems is a verified supplier
Bioz Manufacturer Symbol R&D Systems manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 94
      Buy from Supplier

    Structured Review

    R&D Systems recombinant human cd40l
    Recombinant Human Cd40l, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 15 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+cd40+ligand/Recombinant+Human+CD40+Ligand%2FTNFSF5+(Histidine-tagged)/pmc12901160-269-77-82
    Average 94 stars, based on 15 article reviews
    recombinant human cd40l - by Bioz Stars, 2026-09
    94/100 stars

    Images



    Similar Products

    recombinant human cd40 ligand  (MedChemExpress)
    94
    MedChemExpress recombinant human cd40 ligand
    Recombinant Human Cd40 Ligand, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+cd40+ligand/Recombinant+Human+CD40+Ligand/pm41544754-107-31-36
    Average 94 stars, based on 1 article reviews
    recombinant human cd40 ligand - by Bioz Stars, 2026-09
    94/100 stars
    		  Buy from Supplier
    cd40 ligand  (Sino Biological)
    93
    Sino Biological cd40 ligand
    Cd40 Ligand, supplied by Sino Biological, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+cd40+ligand/Human+CD40L+%2F+CD154+%2F+TNFSF5+Protein/pm41372132-203-0-4
    Average 93 stars, based on 1 article reviews
    cd40 ligand - by Bioz Stars, 2026-09
    93/100 stars
    		  Buy from Supplier
    recombinant human cd40l  (R&D Systems)
    94
    R&D Systems recombinant human cd40l
    Recombinant Human Cd40l, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+cd40+ligand/Recombinant+Human+CD40+Ligand%2FTNFSF5+(Histidine-tagged)/pmc12901160-269-77-82
    Average 94 stars, based on 1 article reviews
    recombinant human cd40l - by Bioz Stars, 2026-09
    94/100 stars
    		  Buy from Supplier
    human cd40l tnfsf5  (R&D Systems)
    94
    R&D Systems human cd40l tnfsf5
    Human Cd40l Tnfsf5, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+cd40+ligand/Recombinant+Human+CD40+Ligand%2FTNFSF5+(108-261)%2C+Animal-Free/pmc12943321-106-23-25
    Average 94 stars, based on 1 article reviews
    human cd40l tnfsf5 - by Bioz Stars, 2026-09
    94/100 stars
    		  Buy from Supplier
    soluble cd40l  (Cell Signaling Technology Inc)
    94
    Cell Signaling Technology Inc soluble cd40l
    Stimulation of B lymphoblastoid cell lines to differentiate into CD20 + FCRL4 + B cells in vitro. (A) Flow cytometry gating strategy for in vitro cultured cells. (B) Histograms showing the expression of functional molecules in B cell lines under different treatments (IFNγ 5 ng/mL; <t>CD40L</t> 100 ng/mL). (C)‐(D) Histograms showing FCRL4 expression in B cell lines under different treatments (LPS 5 µg/mL; SPA 5 µg/mL) with the proportion of FCRL4 − and FCRL4 + cells annotated. (E)‐(F) Bar chart comparing the expression levels of MHC‐I (E) and MHC‐II (F) molecules between the control group and the IFNγ‐treated group. ns P≥0.05; ** p<0.01. (G) Bar chart comparing the expression of FCRL4 molecules between the control group and the CD40L intervention group. * p<0.05. (H) Connected line plot comparing the expression levels of MHC‐I molecules between FCRL4 + and FCRL4 − cells in the same sample after co‐treatment with IFNγ and CD40L. ** p <0.01. (I) Bar chart showing the proportion of FCRL4 + cells in B cells in the control group, LPS‐treated group, and SPA‐treated group. * p <0.05; *** p <0.001; **** p <0.0001. (J) The bar chart compares the signal intensity of FCRL4 expression in ARH‐77 cells in the blank control group, HK‐1 co‐culture group, and HK‐1 lysate stimulated group. ns P≥0.05; ** p <0.01; *** p <0.001.
    Soluble Cd40l, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+cd40+ligand/Human+CD40+Ligand/pmc12955863-387-22-24
    Average 94 stars, based on 1 article reviews
    soluble cd40l - by Bioz Stars, 2026-09
    94/100 stars
    		  Buy from Supplier
    positive control  (R&D Systems)
    94
    R&D Systems positive control
    Stimulation of B lymphoblastoid cell lines to differentiate into CD20 + FCRL4 + B cells in vitro. (A) Flow cytometry gating strategy for in vitro cultured cells. (B) Histograms showing the expression of functional molecules in B cell lines under different treatments (IFNγ 5 ng/mL; <t>CD40L</t> 100 ng/mL). (C)‐(D) Histograms showing FCRL4 expression in B cell lines under different treatments (LPS 5 µg/mL; SPA 5 µg/mL) with the proportion of FCRL4 − and FCRL4 + cells annotated. (E)‐(F) Bar chart comparing the expression levels of MHC‐I (E) and MHC‐II (F) molecules between the control group and the IFNγ‐treated group. ns P≥0.05; ** p<0.01. (G) Bar chart comparing the expression of FCRL4 molecules between the control group and the CD40L intervention group. * p<0.05. (H) Connected line plot comparing the expression levels of MHC‐I molecules between FCRL4 + and FCRL4 − cells in the same sample after co‐treatment with IFNγ and CD40L. ** p <0.01. (I) Bar chart showing the proportion of FCRL4 + cells in B cells in the control group, LPS‐treated group, and SPA‐treated group. * p <0.05; *** p <0.001; **** p <0.0001. (J) The bar chart compares the signal intensity of FCRL4 expression in ARH‐77 cells in the blank control group, HK‐1 co‐culture group, and HK‐1 lysate stimulated group. ns P≥0.05; ** p <0.01; *** p <0.001.
    Positive Control, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+cd40+ligand/Recombinant+Human+CD40+Ligand%2FTNFSF5+(HEK293-expressed)/pmc12852821-440-2-6
    Average 94 stars, based on 1 article reviews
    positive control - by Bioz Stars, 2026-09
    94/100 stars
    		  Buy from Supplier
    positive control 1297  (R&D Systems)
    94
    R&D Systems positive control 1297
    Stimulation of B lymphoblastoid cell lines to differentiate into CD20 + FCRL4 + B cells in vitro. (A) Flow cytometry gating strategy for in vitro cultured cells. (B) Histograms showing the expression of functional molecules in B cell lines under different treatments (IFNγ 5 ng/mL; <t>CD40L</t> 100 ng/mL). (C)‐(D) Histograms showing FCRL4 expression in B cell lines under different treatments (LPS 5 µg/mL; SPA 5 µg/mL) with the proportion of FCRL4 − and FCRL4 + cells annotated. (E)‐(F) Bar chart comparing the expression levels of MHC‐I (E) and MHC‐II (F) molecules between the control group and the IFNγ‐treated group. ns P≥0.05; ** p<0.01. (G) Bar chart comparing the expression of FCRL4 molecules between the control group and the CD40L intervention group. * p<0.05. (H) Connected line plot comparing the expression levels of MHC‐I molecules between FCRL4 + and FCRL4 − cells in the same sample after co‐treatment with IFNγ and CD40L. ** p <0.01. (I) Bar chart showing the proportion of FCRL4 + cells in B cells in the control group, LPS‐treated group, and SPA‐treated group. * p <0.05; *** p <0.001; **** p <0.0001. (J) The bar chart compares the signal intensity of FCRL4 expression in ARH‐77 cells in the blank control group, HK‐1 co‐culture group, and HK‐1 lysate stimulated group. ns P≥0.05; ** p <0.01; *** p <0.001.
    Positive Control 1297, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+cd40+ligand/Recombinant+Human+CD40+Ligand%2FTNFSF5+(HEK293-expressed)/pm41484238-423-2-7
    Average 94 stars, based on 1 article reviews
    positive control 1297 - by Bioz Stars, 2026-09
    94/100 stars
    		  Buy from Supplier
    cd40l release  (MedChemExpress)
    94
    MedChemExpress cd40l release
    Stimulation of B lymphoblastoid cell lines to differentiate into CD20 + FCRL4 + B cells in vitro. (A) Flow cytometry gating strategy for in vitro cultured cells. (B) Histograms showing the expression of functional molecules in B cell lines under different treatments (IFNγ 5 ng/mL; <t>CD40L</t> 100 ng/mL). (C)‐(D) Histograms showing FCRL4 expression in B cell lines under different treatments (LPS 5 µg/mL; SPA 5 µg/mL) with the proportion of FCRL4 − and FCRL4 + cells annotated. (E)‐(F) Bar chart comparing the expression levels of MHC‐I (E) and MHC‐II (F) molecules between the control group and the IFNγ‐treated group. ns P≥0.05; ** p<0.01. (G) Bar chart comparing the expression of FCRL4 molecules between the control group and the CD40L intervention group. * p<0.05. (H) Connected line plot comparing the expression levels of MHC‐I molecules between FCRL4 + and FCRL4 − cells in the same sample after co‐treatment with IFNγ and CD40L. ** p <0.01. (I) Bar chart showing the proportion of FCRL4 + cells in B cells in the control group, LPS‐treated group, and SPA‐treated group. * p <0.05; *** p <0.001; **** p <0.0001. (J) The bar chart compares the signal intensity of FCRL4 expression in ARH‐77 cells in the blank control group, HK‐1 co‐culture group, and HK‐1 lysate stimulated group. ns P≥0.05; ** p <0.01; *** p <0.001.
    Cd40l Release, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+cd40+ligand/Recombinant+Human+CD40+Ligand/10__1172_slash_jci192619-322-18-53
    Average 94 stars, based on 1 article reviews
    cd40l release - by Bioz Stars, 2026-09
    94/100 stars
    		  Buy from Supplier

    Image Search Results


    Stimulation of B lymphoblastoid cell lines to differentiate into CD20 + FCRL4 + B cells in vitro. (A) Flow cytometry gating strategy for in vitro cultured cells. (B) Histograms showing the expression of functional molecules in B cell lines under different treatments (IFNγ 5 ng/mL; CD40L 100 ng/mL). (C)‐(D) Histograms showing FCRL4 expression in B cell lines under different treatments (LPS 5 µg/mL; SPA 5 µg/mL) with the proportion of FCRL4 − and FCRL4 + cells annotated. (E)‐(F) Bar chart comparing the expression levels of MHC‐I (E) and MHC‐II (F) molecules between the control group and the IFNγ‐treated group. ns P≥0.05; ** p<0.01. (G) Bar chart comparing the expression of FCRL4 molecules between the control group and the CD40L intervention group. * p<0.05. (H) Connected line plot comparing the expression levels of MHC‐I molecules between FCRL4 + and FCRL4 − cells in the same sample after co‐treatment with IFNγ and CD40L. ** p <0.01. (I) Bar chart showing the proportion of FCRL4 + cells in B cells in the control group, LPS‐treated group, and SPA‐treated group. * p <0.05; *** p <0.001; **** p <0.0001. (J) The bar chart compares the signal intensity of FCRL4 expression in ARH‐77 cells in the blank control group, HK‐1 co‐culture group, and HK‐1 lysate stimulated group. ns P≥0.05; ** p <0.01; *** p <0.001.

    Journal: Advanced Science

    Article Title: CD20 + FCRL4 + B Cells Activate CD8 + T Cells via MHC‐I Restriction in Nasopharyngeal Carcinoma Anti‐Tumor Immunity

    doi: 10.1002/advs.202514982

    Figure Lengend Snippet: Stimulation of B lymphoblastoid cell lines to differentiate into CD20 + FCRL4 + B cells in vitro. (A) Flow cytometry gating strategy for in vitro cultured cells. (B) Histograms showing the expression of functional molecules in B cell lines under different treatments (IFNγ 5 ng/mL; CD40L 100 ng/mL). (C)‐(D) Histograms showing FCRL4 expression in B cell lines under different treatments (LPS 5 µg/mL; SPA 5 µg/mL) with the proportion of FCRL4 − and FCRL4 + cells annotated. (E)‐(F) Bar chart comparing the expression levels of MHC‐I (E) and MHC‐II (F) molecules between the control group and the IFNγ‐treated group. ns P≥0.05; ** p<0.01. (G) Bar chart comparing the expression of FCRL4 molecules between the control group and the CD40L intervention group. * p<0.05. (H) Connected line plot comparing the expression levels of MHC‐I molecules between FCRL4 + and FCRL4 − cells in the same sample after co‐treatment with IFNγ and CD40L. ** p <0.01. (I) Bar chart showing the proportion of FCRL4 + cells in B cells in the control group, LPS‐treated group, and SPA‐treated group. * p <0.05; *** p <0.001; **** p <0.0001. (J) The bar chart compares the signal intensity of FCRL4 expression in ARH‐77 cells in the blank control group, HK‐1 co‐culture group, and HK‐1 lysate stimulated group. ns P≥0.05; ** p <0.01; *** p <0.001.

    Article Snippet: Following 24 h of stimulation with the following reagents, either individually or in combination: 5 ng/mL human IFNγ (Beyotime, P5664), 100 ng/mL soluble CD40L (CST, #32621), 20 ng/mL LPS (Abiowell, AWH0796), 20 ng/mL SPA (Sigma‐Aldrich, P6031), and 10 μg/mL NPC‐lysate, flow cytometry analysis or an antigen peptide uptake experiment was conducted.

    Techniques: In Vitro, Flow Cytometry, Cell Culture, Expressing, Functional Assay, Control, Co-Culture Assay